UNICA IRIS Institutional Research Information System

LAI, ELEONORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 36.543
NA - Nord America 2.425
AS - Asia 1.463
SA - Sud America 244
AF - Africa 53
OC - Oceania 7
Totale 40.735
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 35.772
US - Stati Uniti d'America 2.318
SG - Singapore 577
CN - Cina 371
SE - Svezia 244
VN - Vietnam 174
BR - Brasile 171
DE - Germania 96
GB - Regno Unito 96
FR - Francia 83
CA - Canada 73
IN - India 69
FI - Finlandia 63
HK - Hong Kong 58
NL - Olanda 38
PL - Polonia 33
AR - Argentina 30
KR - Corea 27
BD - Bangladesh 24
IQ - Iraq 21
ZA - Sudafrica 21
MX - Messico 20
ES - Italia 19
TR - Turchia 19
CO - Colombia 17
IE - Irlanda 16
AT - Austria 15
JP - Giappone 14
ID - Indonesia 13
IR - Iran 12
PH - Filippine 11
PK - Pakistan 11
AE - Emirati Arabi Uniti 10
MA - Marocco 10
UA - Ucraina 10
UZ - Uzbekistan 10
IS - Islanda 8
SA - Arabia Saudita 8
AU - Australia 7
CL - Cile 6
EC - Ecuador 6
JE - Jersey 6
TZ - Tanzania 6
BE - Belgio 5
IL - Israele 5
RU - Federazione Russa 5
VE - Venezuela 5
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
GR - Grecia 4
JM - Giamaica 4
KE - Kenya 4
LT - Lituania 4
MY - Malesia 4
PY - Paraguay 4
RO - Romania 4
AL - Albania 3
DK - Danimarca 3
EG - Egitto 3
KZ - Kazakistan 3
NP - Nepal 3
PT - Portogallo 3
TH - Thailandia 3
BB - Barbados 2
BH - Bahrain 2
CR - Costa Rica 2
DZ - Algeria 2
GH - Ghana 2
LB - Libano 2
LU - Lussemburgo 2
NO - Norvegia 2
OM - Oman 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AM - Armenia 1
BO - Bolivia 1
BY - Bielorussia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
JO - Giordania 1
KH - Cambogia 1
LV - Lettonia 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
PE - Perù 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
Totale 40.735
Salva come PNG Salva come JPEG
Città #
Cagliari 34.094
Uta 1.448
Singapore 330
Ashburn 310
San Jose 200
Nyköping 164
Dallas 150
Chandler 144
Boardman 139
Fairfield 125
Beijing 97
Los Angeles 83
New York 69
Hong Kong 56
Houston 56
Seattle 56
Wilmington 52
Woodbridge 47
Helsinki 44
Ho Chi Minh City 43
Santa Clara 41
Council Bluffs 40
Cambridge 39
Hanoi 39
Lauterbourg 36
Rome 35
San Diego 34
Shanghai 34
Boston 33
Munich 27
Orem 26
The Dalles 26
Hefei 25
Frankfurt am Main 24
Montreal 23
Chicago 21
Redondo Beach 21
Toronto 19
Seoul 18
Amsterdam 17
Chennai 17
Dong Ket 16
London 16
São Paulo 16
Buffalo 15
Warsaw 15
Pune 14
Stockholm 14
Nuremberg 13
Guangzhou 12
Rio de Janeiro 12
Tokyo 11
Milan 10
Tashkent 10
West Lafayette 10
Ann Arbor 9
Brooklyn 9
Poznan 9
Tehran 9
Turku 9
Denver 8
Jacksonville 8
Lappeenranta 8
Manchester 8
Mexico City 8
Reykjavik 8
Casablanca 7
Da Nang 7
Durban 7
Johannesburg 7
Atlanta 6
Bari 6
Cleveland 6
Columbus 6
Dar es Salaam 6
Dearborn 6
Dublin 6
Düsseldorf 6
Medellín 6
Miami 6
Málaga 6
Poplar 6
Portsmouth 6
Santiago de Cali 6
Selargius 6
Turin 6
Vienna 6
Andover 5
Baghdad 5
Casoria 5
Curitiba 5
Dubai 5
Erbil 5
Florence 5
Istanbul 5
Menlo Park 5
Naaldwijk 5
Nanjing 5
Naples 5
Oxford 5
Totale 38.774
Salva come PNG Salva come JPEG
Nome #
BRAF-mutant colorectal cancer, a different breed evolving 3.246
Molecular-biology-driven treatment for metastatic colorectal cancer 2.773
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples 2.702
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression 2.376
From central to sentral (Serum angiogenesis central): Circulating predictive biomarkers to anti-VEGFR therapy 1.913
New therapeutic targets in pancreatic cancer 1.646
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 1.595
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.547
The role of fetal programming in human carcinogenesis - May the Barker hypothesis explain interindividual variability in susceptibility to cancer insurgence and progression? 1.233
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.224
How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world 1.200
null 1.080
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 1.021
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 964
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 941
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 903
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 876
Corrigendum: Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients 777
The Difficult Task of Diagnosing Depression in Elderly People with Cancer: A Systematic Review 759
Uncovering key targets of success for immunotherapy in pancreatic cancer 728
Investigating the Ovarian Microstructure in the Genera Helicolenus and Scorpaena (Teleostei, Sub‐Order Scorpaenoidei) with Implications for Ovarian Dynamics and Spawning 726
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 699
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 679
The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials 651
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma 647
Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice 646
BRCA-mutant pancreatic ductal adenocarcinoma 620
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 602
Immune Checkpoint Inhibitors in the Treatment of HCC 596
EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment 582
Soft tissue epithelioid vascular tumors: a practical clinico pathological diagnostic approach 538
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study 530
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 530
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study 510
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 498
Understanding the user's point of view: when the doctor gets sick with cancer and seeks help 486
null 455
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma 242
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 215
Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics 184
Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors 182
Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular profile 119
Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma 114
The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line 108
Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy 107
Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma 103
Totale 40.873
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.478
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.478
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021269 0 0 0 0 0 0 0 0 0 0 0 269
2021/20223.177 188 149 55 151 152 161 141 346 263 372 436 763
2022/20236.988 748 1.210 929 547 511 612 321 464 397 432 534 283
2023/20247.807 309 210 220 303 527 997 1.040 2.373 371 314 557 586
2024/202511.291 2.841 3.154 1.215 1.382 610 973 511 70 126 123 102 184
2025/20263.790 338 206 293 374 290 298 830 337 219 352 182 71
Totale 40.873